DPYSL5 and paraneoplastic neurologic syndrome: We described CV2/CRMP5‐PNS patients treated by ICI, compared post‐ICI cases with ICI‐naïve, and estimated the overall survival of ICI‐treated patients with CV2/CRMP5‐PNS, Hu‐, and Ma2‐PNS.